Mustang Bio Competitors

Mustang Bio (NASDAQ:MBIO) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk & Volatility

Mustang Bio has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.

Insider and Institutional Ownership

25.8% of Mustang Bio shares are held by institutional investors. Comparatively, 67.5% of Trillium Therapeutics shares are held by institutional investors. 3.4% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Mustang Bio and Trillium Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Mustang Bio and Trillium Therapeutics, as reported by MarketBeat.com.

Mustang Bio currently has a consensus target price of $11.00, indicating a potential upside of 260.66%. Trillium Therapeutics has a consensus target price of $21.8333, indicating a potential upside of 118.77%. Given Mustang Bio's stronger consensus rating and higher possible upside, analysts clearly believe Mustang Bio is more favorable than Trillium Therapeutics.

Earnings and Valuation

This table compares Mustang Bio and Trillium Therapeutics' revenue, earnings per share (EPS) and valuation.

Trillium Therapeutics has higher revenue and earnings than Mustang Bio. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Trillium Therapeutics beats Mustang Bio on 7 of the 12 factors compared between the two stocks.

Enanta Pharmaceuticals (NASDAQ:ENTA) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.

Analyst Recommendations

This is a summary of recent recommendations for Enanta Pharmaceuticals and Mustang Bio, as provided by MarketBeat.

Enanta Pharmaceuticals currently has a consensus price target of $65.2857, suggesting a potential upside of 28.82%. Mustang Bio has a consensus price target of $11.00, suggesting a potential upside of 260.66%. Given Mustang Bio's stronger consensus rating and higher probable upside, analysts clearly believe Mustang Bio is more favorable than Enanta Pharmaceuticals.

Profitability

This table compares Enanta Pharmaceuticals and Mustang Bio's net margins, return on equity and return on assets.

Insider & Institutional Ownership

90.8% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.8% of Mustang Bio shares are owned by institutional investors. 10.9% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Enanta Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Earnings & Valuation

This table compares Enanta Pharmaceuticals and Mustang Bio's gross revenue, earnings per share (EPS) and valuation.

Enanta Pharmaceuticals has higher revenue and earnings than Mustang Bio. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Enanta Pharmaceuticals beats Mustang Bio on 7 of the 13 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings & Valuation

This table compares Prothena and Mustang Bio's gross revenue, earnings per share and valuation.

Mustang Bio has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prothena and Mustang Bio's net margins, return on equity and return on assets.

Institutional and Insider Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 25.8% of Mustang Bio shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Comparatively, 3.4% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Prothena has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Prothena and Mustang Bio, as reported by MarketBeat.com.

Prothena currently has a consensus target price of $29.4286, indicating a potential upside of 18.42%. Mustang Bio has a consensus target price of $11.00, indicating a potential upside of 260.66%. Given Mustang Bio's higher probable upside, analysts plainly believe Mustang Bio is more favorable than Prothena.

Mustang Bio (NASDAQ:MBIO) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Volatility & Risk

Mustang Bio has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mustang Bio and Rhythm Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mustang Bio and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Mustang Bio and Rhythm Pharmaceuticals, as reported by MarketBeat.com.

Mustang Bio currently has a consensus target price of $11.00, indicating a potential upside of 260.66%. Rhythm Pharmaceuticals has a consensus target price of $50.6667, indicating a potential upside of 157.06%. Given Mustang Bio's stronger consensus rating and higher probable upside, analysts plainly believe Mustang Bio is more favorable than Rhythm Pharmaceuticals.

Institutional and Insider Ownership

25.8% of Mustang Bio shares are held by institutional investors. Comparatively, 88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. 3.4% of Mustang Bio shares are held by company insiders. Comparatively, 9.5% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Mustang Bio beats Rhythm Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Phibro Animal Health (NASDAQ:PAHC) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Volatility and Risk

Phibro Animal Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Insider and Institutional Ownership

50.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 25.8% of Mustang Bio shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 3.4% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Phibro Animal Health and Mustang Bio's gross revenue, earnings per share (EPS) and valuation.

Phibro Animal Health has higher revenue and earnings than Mustang Bio. Mustang Bio is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Phibro Animal Health and Mustang Bio, as provided by MarketBeat.com.

Phibro Animal Health presently has a consensus target price of $21.50, suggesting a potential downside of 11.99%. Mustang Bio has a consensus target price of $11.00, suggesting a potential upside of 260.66%. Given Mustang Bio's stronger consensus rating and higher probable upside, analysts clearly believe Mustang Bio is more favorable than Phibro Animal Health.

Profitability

This table compares Phibro Animal Health and Mustang Bio's net margins, return on equity and return on assets.

Summary

Phibro Animal Health beats Mustang Bio on 9 of the 13 factors compared between the two stocks.

G1 Therapeutics (NASDAQ:GTHX) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Risk and Volatility

G1 Therapeutics has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Insider & Institutional Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. Comparatively, 25.8% of Mustang Bio shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Comparatively, 3.4% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for G1 Therapeutics and Mustang Bio, as reported by MarketBeat.com.

G1 Therapeutics presently has a consensus price target of $49.1667, indicating a potential upside of 109.13%. Mustang Bio has a consensus price target of $11.00, indicating a potential upside of 260.66%. Given Mustang Bio's higher possible upside, analysts clearly believe Mustang Bio is more favorable than G1 Therapeutics.

Valuation and Earnings

This table compares G1 Therapeutics and Mustang Bio's top-line revenue, earnings per share and valuation.

G1 Therapeutics is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares G1 Therapeutics and Mustang Bio's net margins, return on equity and return on assets.

Summary

G1 Therapeutics beats Mustang Bio on 6 of the 10 factors compared between the two stocks.